Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
Proposed 100% tariffs target branded pharma imports, with a July 31, 2026 window to negotiate onshoring agreements that could reduce the rate to 20%. Exemptions may apply through MFN-negotiated ...
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results